The Elevated Risk for Venous Thrombosis in Persons with Hyperhomocysteinemia Is not Reflected by the Endogenous Thrombin Potential

 

Present addresses: G. M. J. Bos, is presently a fellow of the Dutch Cancer Foundation; D. T. S. Rijkers, Utrecht University, Faculty of Pharmaceutics, Department of Medicinal Chemistry, Utrecht, The Netherlands; M. den Heijer, Department of Internal Medicine, University of Nijmegen, Nijmegen, The Netherlands

• References

• 1 D’Angelo A, Selhub J.. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
• 2 Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ.. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous tromboembolism. Circulation 1997; 95: 1777-82.
• 3 Heijer Mden, Rosendaal FR, Blom HJ, Gerrits WBJ, Bos GMJ.. Hyper-homocysteinemia and venous thrombosis: a metaanalysis. Thromb Haemost 1998; 80: 824-7.
• 4 Hemker HC, Wielders S, Kessels H, Béguin S.. Continous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70 (04) 617-24.
• 5 Hemker HC, Béguin S.. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74 (01) 134-8.
• 6 Wielders S, Mukheerje M, Michiels J, Rijkers DTS, Cambus J-P, Knebel RWC, Kakkar V, Hemker HC, Béguin S.. The routine determination of the endogenous thrombin potential, first results in different forms of hyper-and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
• 7 Rotteveel RC, Roozendaal KJ, Eijsman L, Hemker HC.. The influence of oral contraceptives on the time-integral of thrombin generation (thrombin potential). Thromb Haemost 1993; 70 (06) 959-62.
• 8 Nicolaes GAF, Thomassen MCLGD, van Oerle R, Hamulyak K, Hemker HC, Tans G, Rosing J.. A prothrombinase-based assay for detection of resistance to activated protein C. Thromb Haemost 1996; 76: 404-10.
• 9 Nicolaes GAF, Thomassen MCLGD, Tans G, Rosing J, Hemker HC.. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coag Fibrinol 1997; 8: 28-38.
• 10 Duchemin J, Pittet JL, Tortary M, Béguin S, Gaussem P, Alhenc-Gelas M, Aiach M.. A new method based on thrombin generation inhibition to detect both protein C and Protein S deficiencies in plasma. Thromb Haemost 1994; 71: 31-338.
• 11 Rijkers DTS, Wielders SJH, Alhenc-Gelas M, Béguin S, Hemker HC.. The thrombomodulin ratio: a screening test for the protein C pathway. Thromb Haemost 1997; 77 Suppl 2251 (Abstract).
• 12 Heijer M, den IA, Brouwer GMJ, Bos HJ, Blom AP, Spaans FR Rosendaal, Thomas CMG, Haak HL, Weijermans PW, Gerrits WBJ.. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998; 18: 356-61.
• 13 Heijer Mden, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ.. Is hyperhomocysteinaemia a risk factor for recurrent venous trombosis?. Lancet 1995; 345: 882-5.
• 14 Heijer Mden, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal F.. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. NEJM 1996; 334: 759-62.
• 15 Welch GN, Loscalzo J.. Mechanisms of disease: Homocysteine and atherothrombosis. NEJM 1988; 338 (15) 1042-50.
• 16 Tsai J, Wang H, Perrella MA, Yoshizumi M, Sibinga NES, Tan LC, Haber E, Hung-Tse Chang T, Schlegel R, Lee M.. Induction of cyclin a gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97: 146-53.
• 17 Kokame K, Kato H, Miyata T.. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. J Biol Chem 1996; 271 (47) 29659-65.
• 18 Homocysteine Lowering Trialist Collaboration. Lowering blood homo-cysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316: 894-8.